Subcutaneous Sumatriptan at Symptom Onset
For this 19-year-old woman with moderate-to-severe migraines occurring 1-2 times weekly that respond poorly to maximum-dose ibuprofen and acetaminophen, the most appropriate next step is subcutaneous administration of sumatriptan at onset of symptoms. This represents escalation to migraine-specific therapy for inadequate response to NSAIDs, which is the guideline-recommended approach 1, 2.
Clinical Reasoning
This patient has failed adequate trials of NSAIDs (ibuprofen at maximum recommended dose) combined with acetaminophen, achieving only "mild relief" and requiring behavioral modifications (dark room, early bedtime) to manage symptoms. According to the most recent 2025 American College of Physicians guideline, when patients use adequate doses of NSAIDs or acetaminophen and still lack sufficient pain relief, the next step is to add a triptan 2.
The guideline framework is clear 1:
- Mild-to-moderate migraines → NSAIDs or combination analgesics with caffeine
- Moderate-to-severe migraines OR mild-to-moderate migraines responding poorly to NSAIDs → Migraine-specific drugs (triptans)
This patient falls squarely into the second category with moderate-to-severe symptoms (nausea, photophobia, phonophobia, visual disturbances) that are inadequately controlled.
Why Subcutaneous Sumatriptan Specifically
Among the answer choices provided, subcutaneous sumatriptan is the only evidence-based acute treatment option. Subcutaneous sumatriptan reaches peak blood concentration in approximately 15 minutes—faster than any other migraine-specific medication—and demonstrates 70-82% efficacy 1. Given her accompanying nausea, a non-oral route offers additional advantages 1, 2.
Why NOT the Other Options
High-flow oxygen therapy is indicated for cluster headaches, not migraine—this would be inappropriate and ineffective.
Oxycodone every 8 hours as needed is explicitly contraindicated. The 2025 ACP guideline states: "Do not use opioids or butalbital for the treatment of acute episodic migraine" 2. Opioid use leads to dependency, rebound headaches, and loss of efficacy 1.
Oral prednisone for 7 days is reserved for status migrainosus (severe continuous migraine lasting up to one week), not for recurrent episodic attacks 1. There is insufficient evidence for steroids in acute episodic migraine treatment.
Referral to neurologist is premature. This patient has not yet received appropriate first-line migraine-specific therapy. Referral would be appropriate only after failure of multiple triptans or when red flags suggest secondary headache.
Critical Next Steps Beyond Acute Treatment
While sumatriptan addresses the immediate question, this patient's increasing frequency (monthly → weekly) and functional impairment (missing classes) are strong indications for preventive therapy 3, 4. With 4-8 headache days per month, she meets criteria for considering prophylaxis. However, the question specifically asks about acute management, making sumatriptan the correct answer.
Important Caveats
- Try 2-3 headache episodes before abandoning triptan therapy 1
- If one triptan fails, try a different triptan—individual response varies 1, 2
- Counsel early administration at symptom onset for maximum efficacy 2
- Monitor for medication overuse headache: limit triptans to <10 days/month 2
- Consider combination therapy (triptan + NSAID) if monotherapy insufficient 2
- Given her age and anxiety, discuss contraception counseling as triptans have pregnancy considerations 2
The patient's anxiety disorder is notable but does not contraindicate triptan use. However, it reinforces the need for comprehensive migraine management including lifestyle modifications and potentially preventive therapy if acute treatment alone proves insufficient.